Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Colorectal Cancer With Hepatic Metastases Clear all

Conditions: Hepatic Metastases, Colon Cancer, Rectal Cancer
Interventions: Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2025
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more

Conditions: Colorectal Cancer Metastatic
Interventions: Nelitolimod; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: Floxuridine, Fluorouracil (5-FU), Conventional surgery, Radiofrequency ablation; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Interventions: Ad-P53, Xeloda, Keytruda, Opdivo; Drug
Lead sponsor: MultiVir, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
Interventions: ATP128, BI 754091, VSV-GP128; Drug
Lead sponsor: Amal Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 3 more

Conditions: Colorectal Carcinoma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions: Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2); Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Tumors
Interventions: Vascular Biogenics (VB)-111, Nivolumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer Metastatic
Interventions: FOLFOX6m, SIR-Spheres microspheres; Drug · Device
Lead sponsor: Sirtex Medical; Industry
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Duarte, California • Orlando, Florida • Pembroke Pines, Florida + 15 more

Conditions: Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastasis Colon Cancer, Colorectal Cancer
Interventions: Y90 TARE, PET/CT, PET/MRI; Radiation · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Goshen Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Goshen, Indiana

Conditions: Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
Interventions: Stereotactic Body Radiation Therapy (SBRT), Botensilimab, Balstilimab; Radiation · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: Postoperative chemotherapy, Perioperative chemotherapy; Procedure
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 283
States / cities: Antioch, California • Duarte, California • Fremont, California + 210 more

Conditions: Metastatic Colorectal Cancer
Interventions: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more

Conditions: Metastases
Interventions: Yttrium-90 (Y-90) resin microspheres; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: gemcitabine hydrochloride, floxuridine, proteomic profiling, matrix-assisted laser desorption/ionization time of flight mass spectrometry, liquid chromatography, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, laboratory biomarker analysis, mass spectrometry, pharmacological study; Drug · Genetic · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Duarte, California

Conditions: Colorectal Neoplasms, Liver Neoplasms
Interventions: Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: irinotecan-eluting beads, hepatic artery embolization; Combination Product · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Liver Neoplasms
Interventions: rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM, rF-CEA(6D)/TRICOM, Recombinant Fowlpox-GM-CSF, Celecoxib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: floxuridine, dexamethasone, oxaliplatin, capecitabine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: floxuridine, irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Little Rock, Arkansas • Lexington, Kentucky • Boston, Massachusetts + 7 more

Conditions: Colorectal Cancer
Interventions: Panitumumab, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Jonesboro, Arkansas • Fort Myers, Florida • Orlando, Florida + 11 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: floxuridine, fluorouracil, leucovorin calcium, adjuvant therapy, conventional surgery; Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions: Radiofrequency Ablation (RFA), Chemotherapy; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Search by objective public record fields.

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases